Objective  To compare the therapeutic effects of amikacin and Omadacycline tosylate on pneumonia caused by carbapenem-resistant community-acquired Klebsiella pneumoniae (CRKP).

Methods  The relevant data of patients with pulmonary infection caused by CRKP who were treated in the Department of Respiratory and Critical Care Medicine of Hangzhou Ninth Hospital from March 2022 to February 2024 were retrospectively analyzed. According to the treatment plans, they were divided into the amikacin group and the omadacycline tosylate group. The time of disappearance of clinical symptoms, changes in inflammatory factors and immune indicators (CD4⁺/CD8⁺ T ratio) and adverse reactions were compared between the two groups of patients.

Results  A total of 86 patients were enrolled, including 41 in the amikacin group and 45 in the omadacycline tosylate group. After treatment, the disappearance time of clinical symptoms such as cough with sputum, lung shadows, and lung rales and the time for body temperature to return to normal in the omadacycline tosylate group were shorter than those in the amikacin group (P﹤0.05). After treatment, the levels of serum white blood cells, neutrophils, C-reactive protein, interleukin-6, and procalcitonin in the omadacycline tosylate group were lower than those in the amikacin group (P﹤0.05). The CD4⁺/CD8⁺ T ratio in the omadacycline tosylate group was significantly higher than that in the amikacin group after treatment (P﹤0.05). During the treatment, there was no statistical difference in the incidence of adverse reactions between the two groups (P﹥0.05).

Conclusion  Compared with amikacin, the treatment of pulmonary infection caused by CRKP with Omadacycline tosylate can shorten the disappearance time of clinical symptoms, improve inflammatory response, enhance immune level, and has no significant adverse reactions, which has significant clinical application value.

1.任静, 黄芬, 徐静. 肺炎克雷伯菌血流感染临床特点及死亡危险因素分析[J]. 西部医学, 2023, 38(1): 87-91, 96. [Ren J, Huang F, Xu J. Clinical characteristics and risk factors analysis of Klebsiella pneumoniae bloodstream infection[J]. Medical Journal of West China, 2023, 38(1): 87-91, 96.] DOI: 10.3969/j.issn.1672-3511.2023.01.015.

2.杨文丽, 王东亮, 冯钧帅, 等. 双组分调节系统对肺炎克雷伯菌多黏菌素耐药机制影响的研究进展[J]. 数理医药学杂志, 2023, 36(10): 779-786. [Yang WL, Wang DL, Feng JS, et al. Research progress on the effect of two-component regulatory system on the mechanism of polymyxin resistance in Klebsiella pneumoniae[J]. Journal of Mathematical Medicine, 2023, 36(10): 779-786.] DOI: 10.12173/j.issn.1004-4337.202305200.

3.江秀娟, 王家珍, 徐少华, 等. 阿米卡星联合哌拉西林舒巴坦对老年重症肺部感染的疗效[J]. 西北药学杂志, 2023, 38(1): 178-182. [Jiang XJ, Wang JZ, Xu SH, et al. Effect of amikacin combined with piperacillin and sulbactam on elderly severe pulmonary infection[J]. Northwest Pharmaceutical Journal, 2023, 38(1): 178-182.] DOI: 10.3969/j.issn.1004-2407.2023.01.032.

4.Zhanel GG, Esquivel J, Zelenitsky S, et al. Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent[J]. Drugs, 2020, 80(3): 285-313. DOI: 10.1007/s40265-020-01257-4.

5.陈海, 李华敏, 刘丽霞, 等. 重症耐碳青霉烯肺炎克雷伯菌肺部感染影响因素及分子流行病学[J]. 中华医院感染学杂志, 2021, 31(13): 2007-2011. [Chen H, Li HM, Liu LX, et al. Influencing factors and molecular epidemiological characteristics of severe carbapenem-resistant Klebsiella pneumoniae pulmonary infection[J]. Chinese Journal of Nosocomiology, 2021, 31(13): 2007-2011.] DOI: 10.11816/cn.ni.2021-203054.

6.中华医学会呼吸病学分会感染学组. 成人抗感染药物下呼吸道局部应用专家共识[J]. 中华结核和呼吸杂志, 2021, 44(4): 322-339. [Infectious Diseases Group, Respiratory Disease Branch, Chinese Medical Association. Expert consensus on local application of adult anti infective drugs in the lower respiratory tract[J]. Chinese Journal of Tuberculosis and Respiratory, 2021, 44(4): 322-339.] DOI: 10.3760/cma.j.cn112147-20200531-00656.

7.《抗菌药物临床试验技术指导原则》写作组. 抗菌药物临床试验技术指导原则[J]. 中国临床药理学杂志, 2014, 30(9): 844-856. [Writing Group of Guidance for Clinical Trials of Anti-bacterial Drugs. Guidance for clinical trials of anti-bacterial drugs[J]. The Chinese Journal of Clinical Pharmacology, 2014, 30(9): 844-856.] DOI: 10.13699/j.cnki.1001-6821.2014.09.030.

8.张翔云, 焦伟杰, 王腾飞, 等. 雾化阿米卡星辅助治疗多重耐药革兰阴性菌肺炎疗效与安全性的Meta分析 [J]. 中国抗生素杂志, 2024, 49(6): 678-685. [Zhang XY, Jiao  WJ, Wang TF, et al. Meta analysis of efficacy and safety of amikacin nebulization as adjuvant therapy for multi-drug resistant Gram-negative bacteria pneumonia[J]. Chinese Journal of Antibiotics, 2024, 49(6): 678-685.] DOI: 10.3969/j.issn.1001-8689.2024.06.011.

9.胡文娟, 杨巧玲, 王学彬, 等. 早产儿感染耐碳青霉烯类肺炎克雷伯菌后的阿米卡星治疗和管理[J]. 中国临床药理学与治疗学, 2024, 29(12): 1401-1408. [Hu WJ, Yang QL, Wang  XB, et al. Amikacin therapy and management of premature infants infected with carbapenem-resistant Klebsiella pneumoniae[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(12): 1401-1408.] DOI: 10.12092/j.issn.1009-2501. 2024.12.010.

10.董璐瑶, 李国庆, 游雪甫, 等. 奥马环素研究进展[J]. 中国医药生物技术, 2020, 15(1): 48-56. [Dong LY, Li GQ, You XF, et al. Research progress on omecycline[J]. Chinese Medicinal Biotechnology, 2020, 15(1): 48-56.] DOI: 10.3969/j.issn.1673-713X.2020.01.009.

11.Galani I, Karaiskos I, Angelidis E, et al. Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2 producing Klebsiella pneumoniae of sequence type 39 during treatment[J]. Eur J Clin Microbiol Infect Dis, 2021, 40(1): 219-224. DOI: 10.1007/s10096-020-04000-9.

12.李耘, 郑波, 薛峰, 等. 中国细菌耐药监测研究（CARST）2021-2022年革兰氏阴性菌监测报告[J]. 中国临床药理学杂志, 2023, 39(23): 3525-3544. [Li Y, Zheng B, Xue F, et al. Antimicrobial susceptibility of Gram-positive organisms: results from China antimicrobial resistance surveillance trial (CARST) program, 2021-2022[J]. The Chinese Journal of Clinical Pharmacology, 2023, 39(23): 3525-3544.] DOI: 10.13699/j.cnki.1001-6821.2023.23.037.

13.Schwanbeck J, Bohne W, Hasdemir U, et al. Detection of a new resistance-mediating plasmid chimera in a blaOXA-48-positive klebsiella pneumoniae strain at a german university hospital[J]. Microorganisms, 2021, 9(4): 720. DOI: 10.3390/microorganisms9040720.

14.徐洋, 韩立卓. 基于属性层次模型的奥马环素临床应用合理性评价[J]. 中国新药杂志, 2025, 34(3): 330-336. [Xu Y, Han  LZ. Evaluation of clinical rationality of omadacycline based on the attribute hierarchical model[J]. Chinese Journal of New Drugs, 2025, 34(3): 330-336.] DOI: 10.2025/j.cnki.1003-3734. 2025.03.018.

15.鹿晓煜, 李爱玲, 王娅宏. 替加环素联合阿米卡星对重症肺炎患者疗效及血清肿瘤坏死因子相关激活蛋白、血管细胞黏附因子表达的影响[J]. 中国药物应用与监测, 2023, 20(5): 324-329. [Lu XY, Li AL, Wang YH. Effect of tigecycline combined with amikacin on severe pneumonia and expression of serum CD40L and VCAM-1[J]. Chinese Journal of Drug Application and Monitoring, 2023, 20(5): 324-329.] DOI: 10.3969/j.issn.1672-8157.2023.05.012.

16.王玥坤, 高茗, 吴波, 等. 45例次奥马环素治疗的疗效及安全性初探[J]. 药学与临床研究, 2024, 32(6): 556-559. [Wang  YK, Gao M, Wu B, et al. A preliminary study on the efficacy and safety of omadacycline treatment in 45 cases[J]. Pharmaceutical and Clinical Research, 2024, 32(6): 556-559.] DOI: 10.13664/j.cnki.pcr.2024.06.021.

17.葛鹏程, 冯雪, 李聪聪, 等. 奥马环素与硫酸黏菌素治疗泛耐药鲍曼不动杆菌肺内感染的效果[J]. 创伤与急危重病医学, 2025, 13(1): 69-70, 74. [Ge PC, Feng X, Li CC, et al. The efficacy of omacycline and sulfamethoxazole in the treatment of pan resistant Acinetobacter baumannii pulmonary infections[J]. Trauma and Critical Care Medicine, 2025, 13(1): 69-70, 74.] DOI: 10.16048/j.issn.2095-5561.2025.01.14.

18.Heine HS, Drusano G, Purcell BK, et al. Omadacycline is active in vitro and in vivo against ciprofloxacinresistant Bacillus anthraciss[J]. Antimicrob Agents Chemother, 2024, 68(9): e0059524. DOI: 10.1128/aac.00595-24.

19.Gill CM, Fratoni AJ, Shepard AK, et al. Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis[J]. J Antimicrob Chemother, 2022, 77(5): 1372-1378. DOI: 10.1093/jac/dkac055.

20.Sakoulas G. Linezolid versus omadacycline in diabetic soft tissue infections: a signal of different adjunctive immunological properties?[J]. J Antimicrob Chemother, 2022, 77(6): 1503-1505. DOI: 10.1093/jac/dkac030.

21.El Ghali A, Morrisette T, Alosaimy S, et al. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections：a retrospective，multicenter cohort of real-world health outcomes[J]. Antimicrob Agents Chemother, 2023, 67(10): e0082423. DOI: 10.1128/aac.00824-23.